MILFORD, Mass., Oct. 7, 2013 /PRNewswire/ -- Dr. Graham R. Foster and his team from Queen Mary, University of London, London, United Kingdom, will be presenting a poster titled "Pangenotypic anti-HCV activity of SB 9200 assessed in the 'Capture-fusion' replication assay" (Abstract No. 473) at the 64th Annual Meeting of The American Association for the Study of Liver Diseases (AASLD), November 1-5, 2013, Washington, DC. Details can now be viewed at the AASLD website at www.aasld.org.
The Poster is scheduled for presentation on Saturday, November 2, 2013, 2:00 pm 7:30 pm EDT.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is engaged in the discovery and development of an entirely new class of pharmaceuticals based on the Company's proprietary SMNH, "Small Molecule Nucleic Hybrid" technology program. The company's lead compound, SB 9200, a potential breakthrough drug for the treatment of HCV and HBV, is currently in Ph. 1 clinical studies for HCV. In addition, the Company has preclinical programs for Respiratory Syncytial Virus (RSV) infections, a Broad-Spectrum Antiviral agent, and COPD. For more information, please visit our website: www.springbankpharm.com
Contact: Douglas Jensen (508) 473-5993 Ext.105
SOURCE Spring Bank Pharmaceuticals, Inc.